On September 21, 2023, JURA Bio, a biotechnology company developing immune-based therapeutics using machine learning and synthetic biology, announced a research collaboration with Syena, a cell therapy product company and subsidiary of Replay, a genome writing company, to develop T cell receptor (TCR) based therapies. In addition, JURA Bio announced a $16.1 million financing led by Michael Chambers, John Ballantyne, Fontus Capital, and Josh Elkington, which will accelerate the mapping of the adaptive immune system.

Wilson Sonsini Goodrich & Rosati advised JURA Bio on both the financing transaction and the collaboration agreement.

A Wilson Sonsini corporate team led by Jennifer Fang, Mark Solakian, Amanda Creedon, and Tamara Labanowski advised JURA Bio on the financing transaction. A Wilson Sonsini technology transactions team led by Farah Gerdes and Sai Upadhyayula advised JURA Bio on the collaboration agreement.

For more information, please see JURA Bio’s press release.